Moon Eun-Sang – CEO, SillaJen – South Korea
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
SillaJen, Inc. is a privately-held biotechnology company focusing on engineering and developing best-in-class oncolytic immunotherapeutics. SillaJen has Korean offices in Busan (R&D), at Pusan National University (PNU), and in Seoul (finance, management & legal). SillaJen also has Clinical R&D, regulatory affairs and CMC capabilities in San Francisco, California, one of the world’s leading biotechnology centers and the “birthplace” of the biotech industry. SillaJen products are engineered from vaccinia which has unique attributes as an oncolytic immunotherapy.
Contact Details
Busan Office
Seoul Office
San Francisco Office
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
Bernhard Brender, general manager of Grand Hilton Seoul, discusses the role of his conference centre and the meetings, incentives, conferences and exhibitions (MICE) industry in general in the economic development…
Thibault Janssens, managing director of Bolloré Logistics Korea, shares his expert opinion on the Asian logistics market, and explains how a constant customer-centric focus catering to the specific needs of…
Kukjeon, originally a leading Korean pharmaceutical wholesaler, has in recent years expanded into API manufacturing. Its president, Jay Hong, explains his high-risk strategy to pursue new API business opportunities, and…
YH Shin, CEO of Dr.G, one of Korea’s most successful dermo-cosmetic brands, shares the reasons why he decided to become a dermatologist and later start his own cosmetic company. He…
Historically, Handok has been the entry point of multinational companies to Korea. Now Handok is reinventing itself as a total healthcare company with global ambitions. Its chairman and CEO, Young-jin…
Nic Horridge was recently appointed president of Roche Korea, having spent an extended period in emerging Asian markets. He shares his vision for the Korean affiliate, focused on bringing Roche’s…
iCure is a Korean company applying its advanced transdermal delivery technology to pharmaceuticals and dermo-cosmetics. The company has developed the first-ever transdermal patch for donepezil to reach Phase III clinical…
Myung-Kyu Lee, vice president of the Korea Cosmetic Association, explains how the association helps its member companies both at home and abroad, breaks down the implications of new local and…
Shin Poong is one of the oldest pharmaceutical companies in Korea. Established after the Korean War, the company’s original mission was to provide high-quality and affordable generic medicines to the…
Cure Therapeutics is a startup developing gene and cell therapies in Korea. Its founder David Kim explains where his passion for regenerative therapies stems from, breaks down the main hurdles…
After a long career at leading diagnostics companies in research and business development roles, Young Kuk Yun decided to use his accumulated experience to start a venture dedicated to providing…
Two leading executive recruitment specialists – DHR International’s Helen Park and Egon Zehnder’s Eugene Kim – outline the qualities they look for when hiring pharma country managers for the challenging…
See our Cookie Privacy Policy Here
